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Abstract
Our scientific knowledge of bullous pemphigoid (BP) has dramatically progressed in recent years.
However, despite the availability of various therapeutic options for the treatment of inflammatory
diseases, only a few multicenter controlled trials have helped to define effective therapies in BP. A
major obstacle in sharing multicenter-based evidences for therapeutic efforts is the lack of
generally accepted definitions for the clinical evaluation of patients with BP. Common terms and
end points of BP are needed so that experts in the field can accurately measure and assess disease
extent, activity, severity, and therapeutic response, and thus facilitate and advance clinical trials.
These recommendations from the International Pemphigoid Committee represent 2 years of
collaborative efforts to attain mutually acceptable common definitions for BP and proposes a
disease extent score, the BP Disease Area Index. These items should assist in the development of
consistent reporting of outcomes in future BP reports and studies.
Keywords
bullous pemphigoid; consensus; definitions; outcome measures; severity score
Bullous pemphigoid (BP) is a common autoimmune bullous disease typically affecting the
elderly. There have been only a handful of well-designed randomized controlled trials
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assessing the effectiveness of therapies for BP.1 In relatively rare diseases where it is
difficult to include enough patients to have sufficient power to compare different treatments,
meta-analysis is a powerful tool that is used to pool data across trials. However, it is
impossible to compare the therapeutic outcomes from the majority of these BP studies using
meta-analysis, as they have varying definitions and outcome measures.
PURPOSE
The purpose of this statement is to provide appropriate definitions for the various stages of
disease activity, define therapeutic end points in BP, and to propose an objective disease
extent measure that can be used in clinical trials. The use of the same definitions and
outcome measures makes the results of trials more comparable. Since definitions and
outcome measures for pemphigus2–4 have been published, most trials in pemphigus and
reports have begun adopting these systems or referring to them when their existing trials
using other measures were unable to show a difference.5
METHODS
An international BP definitions committee was organized in 2008, at the point when the
international pemphigus definitions committee completed its similar work on pemphigus.2
The committee was an expansion of the first committee and convened 7 times over 2 years
to discuss the appropriate definitions. These meetings were held at the American Academy
of Dermatology (AAD) annual meeting in San Antonio, TX, in 2009 (D. F. M. and V. P.
W.); European Society for Dermatologic Research in Budapest, Hungary, in 2009 (D. F. M.
and P. J.); the European Academy of Dermatovenereology in Berlin, Germany, in 2009 (D.
F. M. and L. B.); the AAD in Miami, FL, in 2010 (D.F.M. and V. P. W.); the Pemphigus
2010 Meeting in Bern, Switzerland (V. P.W. and D. F. M.); and the International Pemphigus
and Pemphigoid Meeting at the National Institutes of Health in November 2010 (V. P. W.
and D. F. M.), in Bethesda, MD. The final meeting was held at the AAD in 2011 in
NewOrleans, LA (D. F. M. and V. P. W.). Meetings were supported in part by local
dermatology societies. The draft definitions and end points were electronically mailed to the
larger group, allowing for comments between meetings.
THE RECOMMENDATIONS
Observation points
The end points are illustrated and summarized (Fig 1 and Table I).
Early end points
“Baseline” is the point at which a physician starts treatment for BP.
“Control of disease activity” (disease control; beginning of consolidation phase) is defined
as the point at which new lesions or pruritic symptoms cease to form and established lesions
begin to heal. The time to disease control is the time between baseline and this control point.
“End of the consolidation phase” is defined as the time at which no new lesions or pruritic
symptoms have developed for a minimum of 2 weeks and the majority (approximately 80%)
of established lesions has healed. At this point tapering of corticosteroids often occurs. The
length of the consolidation phase is the time between disease control and the end of
consolidation phase.
“Transient lesions” are new lesions that heal within 1 week or pruritus lasting less than a
week and clearing without treatment.
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“Nontransient lesions” are new lesions that do not heal within 1 week or pruritus continuing
more than a week with or without treatment.
Intermediate end points
During this period, the corticosteroids and other treatments are usually being tapered, but for
some patients medication doses do not change because of flaring with attempts to taper
treatment. “Complete remission during tapering” is the absence of nontransient lesions while
the patient is receiving more than minimal therapy. There is no minimum time point here as
the patient is under control but has not yet reached the desired outcome of disease remission
on minimal or no therapy.
Late observation end points
Late observation end points of disease activity are identified as: (1) complete remission off
therapy; and (2) complete remission on therapy, both of which only apply to patients who
have had no new or established lesions for at least 2 months. “Complete remission off
therapy” is defined as an absence of new or established lesions or pruritic symptoms while
the patient is off all BP therapy for at least 2 months.
“Complete remission on therapy” is defined as the absence of new or established lesions or
pruritus while the patient is receiving minimal therapy for at least 2 months. “Minimal
therapy” is defined as less than or equal to 0.1 mg/kg/d of prednisone (or the equivalent) or
20 g/wk of clobetasol propionate and/or minimal adjuvant or maintenance therapy for at
least 2 months, as shown in Fig 1 and discussed further below.
Minimal adjuvant therapy in BP corresponds to the following doses or less: methotrexate 5
mg/wk; azathioprine 0.7 mg/kg/d (with normal thiopurine s-methyltransferase level);
mycophenolate mofetil 500 mg/d; mycophenolic acid 360 mg/d; or dapsone 50 mg/d. There
has only been one small randomized controlled trial on tetracycline and niacinamide,6 which
was underpowered because of low numbers and was unable to demonstrate a difference.
Nevertheless, the committee’s expert opinion is that full therapeutic doses of the
tetracyclines may work in localized forms of BP. As the tetracycline class of drugs is
relatively nontoxic, the full therapeutic dose was listed among minimal therapies for BP.
“Partial remission off therapy” is defined as the presence of transient new lesions that heal
within 1 week without treatment and while the patient is off all BP therapy for at least 2
months.
“Partial remission on minimal therapy” is defined as the presence of transient new lesions
that heal within 1 week while the patient is receiving minimal therapy.
A newer term, “mild new activity,” refers to fewer than 3 lesions a month (blisters,
eczematous lesions, or urticarial plaques) that do not heal within 1 week, or the extension of
established lesions or pruritus once per week but less than daily, in a patient who has
achieved disease control. This term was not included in the pemphigus definitions but the
committee thought that it might be important to capture this phase during studies to
determine if some patients with BP and certain characteristics or treatments experienced
new mild activity not significant enough to constitute a flare. In this way, it could be
determined in the future if these patients with BP might benefit from a change of treatment
plan or not.
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The terms “relapse” and “flare” are used interchangeably and are defined as the appearance
of 3 or more new lesions a month (blisters, eczematous lesions, or urticarial plaques) or at
least one large (>10 cm diameter) eczematous lesion or urticarial plaque that does not heal
within 1 week, or the extension of established lesions or daily pruritus in a patient who has
achieved disease control.
Treatment failure
“Failure of therapy for initial control” is defined as the development of new nontransient
lesions or continued extension of old lesions, or failure of established lesions to begin to
heal or daily pruritus despite certain strengths of corticosteroids with or without higher doses
of adjuvants. The dose of prednisone defined as treatment failure is 0.75 mg/kg/d equivalent
for minimum of 3 weeks. This dose was selected because the Cochrane review of
interventions for BP1,7 determined that in acute BP there was no purpose in using
prednisone at a higher dose than this. Topical clobetasol propionate at 40 g/d for 4 weeks
was selected on the basis of the randomized controlled trials conducted by the French
group.8,9 Other therapies include tetracycline at full doses for 4 weeks; dapsone 1.5 mg/kg/d
for 4 weeks; methotrexate 15 mg/wk (if >60 kg and no major renal impairment) for 4 weeks;
azathioprine 2.5 mg/kg/d for 4 weeks (if thiopurine s-methyltransferase level is normal); or
mycophenolate mofetil 40 mg/kg/d (if normal renal function, otherwise according to age/
creatinine clearance) for 4 weeks. The definition does not imply these drugs and their
respective doses are equivalent in therapeutic efficacy. Rather it provides a standardized
agreement as to what can be defined as a failure of therapy.
BP disease activity index
Like the Pemphigus Disease Area Index (PDAI),3 the BP Disease Area Index (BPDAI)
measure has separate scores for skin and mucous membrane activity. Damage scores are
separate as well and are included to remind physicians that not all visible lesions in BP
represent active disease. Areas of the skin predominantly affected in BP10 were taken into
account when selecting the skin sites so that trials would better differentiate clinical
response in BP. Hence, additional weighting was given to the arms and legs and less
emphasis to the face and scalp, slightly different from the PDAI. The mucous membrane
areas were retained from the PDAI even though it is relatively rare to see mucous membrane
involvement in BP, so that the activity could be compared with extent of mucous membrane
involvement in different autoimmune bullous diseases. There are separate columns for the
extent of blistering and for the urticarial/eczematous lesions that may be more extensive in
BP.
As a major symptom that may herald the onset and recurrence of BP is pruritus, a separate
subjective component of the BPDAI is proposed to measure the severity of this (Fig 2).
Naturally, other causes of pruritus in the elderly must be excluded, such as xerosis,
dermatitis, renal impairment, liver impairment, and scabies. Providing that only pruritus
related to BP is considered in the definitions and scored, this system can be used to
subjectively grade the intensity of pruritus using a visual analog scale to answer the
question, “How severe is your itching today?” and the patient marks an “x” on the 0- to 10-
cm line where 0 is no itch and 10 is maximal itching. The degree of itching is measured as
the distance in centimeters from 0, out of 10. This is repeated for the severity overall of
itching in the past week and month. A total score is calculated from this out of 30. If the
patient with BP is incapable of completing a reliable visual analog scale rating, for example,
as a result of dementia, then the degree of pruritus is inferred, based on the extent of
excoriations alone, also scored out of 30 (Fig 2). This subjective itch score will not be
combined with the objective part of the BPDAI (Fig 3). Eventually, a quality-of-life tool for
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BP will be necessary as well. The BPDAI will be undergoing validation studies, similar to
the partial validation done thus far with the PDAI.3
DISCUSSION AND CONCLUSION
Despite many trials evaluating therapeutic options for BP, it has been difficult to compare
the results from these trials because of the large number of end points and definitions of
disease. The formation of an international committee of bullous disease experts able to meet
face to face on a regular basis has provided a mechanism for developing agreement on these
issues for BP. This statement with agreed-upon common definitions, and the ongoing
discussion and refinement of proposed common measurements for patients with BP, are the
initial and necessary steps toward progress in the clinical evaluation and therapy of BP.
Further progress and advancement will require a continued unified effort.
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Pictorial depiction of end points in bullous pemphigoid.
Murrell et al. Page 8














Subjective Bullous Pemphigoid (BP) Disease Area Index (BPDAI ) pruritus score. VAS,
Visual analog scale.
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Objective bullous pemphigoid disease area index
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Table I
Definitions for bullous pemphigoid
Early observation points
Baseline Day that BP therapy is started by physician
Control of disease activity Time at which new lesions cease to form and established lesions begin to heal or pruritic symptoms start to
abate




Time interval from baseline to control of disease activity
End of consolidation phase Time at which no new lesions have developed for minimum of 2 wk and approximately 80% of lesions
have healed and pruritic symptoms are minimal
Intermediate observation end points
Transient lesions New lesions that heal within 1 wk or pruritus lasting <1 wk and clearing without treatment
Nontransient lesions New lesions that do not heal within 1 wk or pruritus continuing >1 wk with or without treatment
Complete remission during
tapering
Absence of nontransient lesions while patient is receiving more than minimal therapy
Late observation end points
Minimal therapy ≤ 0.1 mg/kg/d Of prednisone (or equivalent) or 20 g/wk of clobetasol propionate and/or minimal adjuvant
or maintenance therapy
Minimal adjuvant therapy and/or
maintenance therapy
Following doses or less: methotrexate 5 mg/wk; azathioprine 0.7 mg/kg/d (with normal thiopurine s-
methyltransferase level); mycophenolate mofetil 500 mg/d; mycophenolic acid 360 mg/d; or dapsone 50
mg/d
Partial remission on minimal
therapy
Presence of transient new lesions that heal within 1 wk while patient is receiving minimal therapy for at
least 2 mo
Complete remission on minimal
therapy
Absence of new or established lesions or pruritus while patient is receiving minimal therapy for at least 2
mo
Partial remission off therapy Presence of transient new lesions that heal within 1 wk without treatment while patient is off all BP
therapy for at least 2 mo
Complete remission off therapy Absence of new or established lesions or pruritus while patient is off all BP therapy for at least 2 mo
Mild new activity <3 Lesions/mo (blisters, eczematous lesions, or urticarial plaques) that do not heal within 1 wk, or
extension of established lesions or pruritus once/wk but less than daily in patient who has achieved disease
control; these lesions have to heal within 2 wk
Relapse/flare Appearance of ≥3 new lesions/mo (blisters, eczematous lesions, or urticarial plaques) or at least one large
(>10 cm diameter) eczematous lesion or urticarial plaques that do not heal within 1 wk, or extension of
established lesions or daily pruritus in patient who has achieved disease control
Failure of therapy for initial
control
Development of new nontransient lesions or continued extension of old lesions, or failure of established
lesions to begin to heal or continued pruritus despite:
Clobetasol propionate 40 g/d for 4 wk; or
Prednisone 0.75 mg/kg/d equivalent for minimum of 3 wk with or without drugs used for maintenance
therapy; or
A tetracycline on full dosing for 4 wk; or
Dapsone 1.5 mg/kg/d for 4 wk; or
Methotrexate 15 mg/wk (if >60 kg and no major renal impairment) for 4 wk; or
Azathioprine 2.5 mg/kg/d for 4 wk (if thiopurine s-methyltransferase level is normal); or
Mycophenolate mofetil 40 mg/kg/d (if normal renal function, otherwise according to age/creatinine
clearance) for 4 wk
BP, Bullous pemphigoid.
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